Immune Recovery of Lymphocyte Subsets 6 Years after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Lymphoproliferative Diseases. A Comparison between NHL, HD and MM in Group of 149 Patients
- 1 October 2004
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (10) , 2063-2070
- https://doi.org/10.1080/10428190410001714052
Abstract
To evaluate the normalization of lymphocyte subsets several years after autologous peripheral blood stem cell transplantation (aPBSCT) and to detect any differences based on the underlying lymphoproliferative diseases, we analyzed the immunological recovery of 149 patients with Non Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD), Multiple Myeloma (MM). Lymphocyte recovery was assessed before the transplant, on days 15, 30, 60, 90, 120 and on years 1, 2, 4, 6. Analysis of a total of 709 lymphocytes, including total lymphocyte count, CD3 +, CD4 +, CD8 +, CD4 +/CD8 + ratio, CD19 +, CD3 + HLA-DR +, CD16 + 56 +, was performed. The normalization of total lymphocyte counts was achieved between days 14 to 22 following PBSCT. CD3 + cells count showed a normalization after 2 years in the HD and NHL groups and after 4 years in MM group. CD4 + subset achieved normalization during the sixth year in the 3 groups. The CD8 + and CD19 + lymphocytes subsets achieved normal values in the 3 groups at day 60 and at day 120 respectively. CD16 + 56 + and CD3 +/HLA-DR + lymphocytes showed median values above the normal range starting from day 30. Immunological recovery was similar in all 3 groups. Moreover, the recovery of all subsets evaluated was similarly demonstrated within 6 years after aPBSCT.Keywords
This publication has 11 references indexed in Scilit:
- Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphomaBlood, 2001
- Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patientsBlood, 2001
- Immune reconstitution after autologous selectedperipheral blood progenitor cell transplantation:comparison of two CD34+ cell‐selection systemsTransfusion, 2001
- Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitutionThe Lancet, 2000
- Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplantsBritish Journal of Haematology, 2000
- Optimal timing of G-CSF administration after CD34+immunoselected peripheral blood progenitor cell transplantationBone Marrow Transplantation, 1999
- CD34+ Cell Selection from Frozen Cord Blood Products Using the Isolex 300i and CliniMACS CD34 Selection DevicesJournal of Hematotherapy, 1998
- A Comparison of Two Different Systems for CD34+ Selection of Autologous or Allogeneic PBSC CollectionsJournal of Hematotherapy, 1998
- Lymphoid Reconstitution After Autologous PBSC Transplantation With FACS-Sorted CD34+ Hematopoietic ProgenitorsBlood, 1998
- Transplantation of CD34+ Hematopoietic Progenitor CellsCancer Investigation, 1996